Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WINIT-BC: Mitazalimab +/- Nivolumab in Resectable Breast Cancer
NCT07319195Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitazalimab in breast cancer (6 arms). Primary endpoints: Occurrence of Grade 3 or higher adverse events as assessed by CTCAE v5.0 at 30 days and Feasibility of CD40 agonist with/without PD-1 inhibitor prior to surgery at 14 days. Started Apr 2026; status: recruiting.
02
Drugs
mitazalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07319195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07319195.